AR017095A1 - 1,2,3,4,5,6-hexahidro-2,6-metano-3-benzazocin-10-oles, procedimiento para su preparacion, metodo para la elaboracion de un compuesto intermedio del procedimiento, preparacion farmaceutica que los contiene y su empleo como o en medicamento - Google Patents

1,2,3,4,5,6-hexahidro-2,6-metano-3-benzazocin-10-oles, procedimiento para su preparacion, metodo para la elaboracion de un compuesto intermedio del procedimiento, preparacion farmaceutica que los contiene y su empleo como o en medicamento

Info

Publication number
AR017095A1
AR017095A1 ARP980104530A ARP980104530A AR017095A1 AR 017095 A1 AR017095 A1 AR 017095A1 AR P980104530 A ARP980104530 A AR P980104530A AR P980104530 A ARP980104530 A AR P980104530A AR 017095 A1 AR017095 A1 AR 017095A1
Authority
AR
Argentina
Prior art keywords
methyl
mean
preparation
procedure
mean hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
ARP980104530A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH Co KG
Original Assignee
Boehringer Ingelheim Pharma GmbH Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma GmbH Co KG filed Critical Boehringer Ingelheim Pharma GmbH Co KG
Publication of AR017095A1 publication Critical patent/AR017095A1/es
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D221/00Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22Bridged ring systems
    • C07D221/26Benzomorphans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

1,2,3,4,5,6-hexahidro-2,6-metano-3-benzazocin-10-oles de formula general (I) en la cual: X puede significar un enlace sencillo, -O-, alquileno C1-4, unpuente de alquileno C1-8 que puede estar ramificado o sin ramificar, y puede presentar, encualquie r posicion del puente, uno o dos átomos de oxígeno,preferentemente O-alquileno C1-3, -O-CH2-CH2-O-, -O-CH2-CH2-NH-; R1 puede significar hidrogeno, metilo, etilo, fenilo; R2 puede significar hidrogeno, metilo;R3 puede significar hidrogeno,fluoro, clo ro, bromo, hidroxi, metilo, metoxi; R4 puede significar hidrogeno, metilo, etilo; R5 puede significar hidrogeno,metilo, etilo; R6 puede significar hidrogeno, metilo, etilo; R7 puede significar t-butilo, ciclohexilo, fenilo eventualmentesustituido co n R9 y R10, quepueden ser iguales o diferentes, un compuesto de formula (II); R8 puede significar hidrogeno, alquilo C1-4; Z puede significar oxígeno, NH, azufre; R9 puedesignificar hidrogeno, metilo, fluoro, cloro, bromo, metoxi; R10puede significa r hidrogeno, metilo, fluoro, cloro, bromo, metoxi; eventualmente en forma de losisomeros opticos individuales, mezclas de los enantiomeros individuales o racematos, así como en forma de las bases libres o de las correspondientessales poradicion de á cido con ácidos farmacologicamente inocuos. Los compuestos del invento son blanqueadores del canal de sodio dependiente del potencial.Procedimiento para su preparacion, método para la elaboracion de un compuesto intermedio delprocedimiento, preparac ion farmacéutica que los contiene y suempleo como o en medicamentos destinados al tratamiento terapéutico de isquemias cerebrales de diversa génesis, enfermedades neurodegenerativas, estadoepiléptico, hipoglicemia, hipoxia,anoxia, trauma cerebral, e dema cerebral, accidente apoplético cerebral, asfixia perinatal, esclerosis lateral amilotropa,enfermedad de Huntington, enfermedad de Alzheimer, enfermedad de Parkinson, desordenes bipolares, ciclofrenia, hipotonia,infarto cardíaco, trastornos delr itmo cardíaco, angina de pecho, dolor, anestesia o anestesia local.
ARP980104530A 1997-09-12 1998-09-11 1,2,3,4,5,6-hexahidro-2,6-metano-3-benzazocin-10-oles, procedimiento para su preparacion, metodo para la elaboracion de un compuesto intermedio del procedimiento, preparacion farmaceutica que los contiene y su empleo como o en medicamento Pending AR017095A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19740110A DE19740110A1 (de) 1997-09-12 1997-09-12 Substituierte 1,2,3,4,5,6-Hexahydro-2,6-methano-3-benzazocin-10-ole, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel

Publications (1)

Publication Number Publication Date
AR017095A1 true AR017095A1 (es) 2001-08-22

Family

ID=7842134

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980104530A Pending AR017095A1 (es) 1997-09-12 1998-09-11 1,2,3,4,5,6-hexahidro-2,6-metano-3-benzazocin-10-oles, procedimiento para su preparacion, metodo para la elaboracion de un compuesto intermedio del procedimiento, preparacion farmaceutica que los contiene y su empleo como o en medicamento

Country Status (38)

Country Link
US (1) US6455538B1 (es)
EP (1) EP1015433B1 (es)
JP (1) JP3827528B2 (es)
KR (1) KR100601008B1 (es)
CN (1) CN1166640C (es)
AR (1) AR017095A1 (es)
AT (1) ATE267811T1 (es)
AU (1) AU751036B2 (es)
BG (1) BG64418B1 (es)
BR (1) BR9812443A (es)
CA (1) CA2302347C (es)
CO (1) CO5011117A1 (es)
CZ (1) CZ296909B6 (es)
DE (2) DE19740110A1 (es)
DK (1) DK1015433T3 (es)
EE (1) EE04398B1 (es)
ES (1) ES2222612T3 (es)
HR (1) HRP980502B1 (es)
HU (1) HUP0004588A3 (es)
ID (1) ID24173A (es)
IL (1) IL134572A (es)
MY (1) MY120550A (es)
NO (1) NO315650B1 (es)
NZ (1) NZ503710A (es)
PE (1) PE122899A1 (es)
PL (1) PL198486B1 (es)
PT (1) PT1015433E (es)
RS (1) RS49888B (es)
RU (1) RU2218334C2 (es)
SA (1) SA98190765B1 (es)
SK (1) SK284670B6 (es)
TR (1) TR200000697T2 (es)
TW (1) TW505645B (es)
UA (1) UA61973C2 (es)
UY (2) UY25175A1 (es)
WO (1) WO1999014199A1 (es)
YU (1) YU12000A (es)
ZA (1) ZA988285B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19826365A1 (de) * 1998-06-12 1999-12-16 Gruenenthal Gmbh Verwendung von Benzomorphanderivaten als Analgetikum
US6355652B1 (en) 1999-11-27 2002-03-12 Boehringer Ingelheim Pharma Kg Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocines and their use as pharmaceutical compositions
DE19957156A1 (de) * 1999-11-27 2001-05-31 Boehringer Ingelheim Pharma Substituierte 1,2,3,4,5,6-Hexahydro-2,6-methano-3-benzazocine und ihre Verwendung als Arzneimittel
US6683089B2 (en) 2002-02-02 2004-01-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg N-allyoxyethyl-1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocine-10-ols
DE10204276A1 (de) * 2002-02-02 2003-08-07 Boehringer Ingelheim Pharma N-Allyloxyethyl-1,2,3,4,5,6-Hexahydro-2,6-methano-3-benzazocine und ihre Verwendung als Arzneimittel
US20040019075A1 (en) * 2002-05-29 2004-01-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg New formulation for the parenteral application of crobenetine
DE10223783A1 (de) * 2002-05-29 2003-12-11 Boehringer Ingelheim Pharma Neue Formulierung zur parenteralen Applikation eines Na-Kanal-Blockers
US6828311B2 (en) 2002-05-29 2004-12-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Formulation for the parenteral application of a sodium channel blocker
US20030235576A1 (en) * 2002-06-15 2003-12-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg New drug combinations for the treatment of ischaemic conditions
DE10226814A1 (de) * 2002-06-15 2004-01-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkombinationen zur Behandlung ischämischer Zustände
RS54522B1 (en) 2005-12-22 2016-06-30 Newron Pharmaceuticals S.P.A. 2-Phenylethylamino Derivatives as Modulators of Calcium and (or Sodium) Channels
CN101687773B (zh) 2007-06-15 2014-07-30 纽朗制药有限公司 取代的2-[2-(苯基)乙氨基]烷酰胺衍生物及其作为钠和/或钙通道调节剂的应用
EA022973B1 (ru) 2011-06-27 2016-03-31 Ньюрон Фармасьютикалс С.П.А. Фторированные арилалкиламинокарбоксамидные производные

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2828039A1 (de) * 1978-06-26 1980-01-10 Boehringer Sohn Ingelheim 2-(2-alkoxyethyl)-2'-hydroxy-6,7-benzomorphane deren saeureadditionssalze diese enthaltende arzneimittel und verfahren zu deren herstellung
US4208523A (en) 1978-11-30 1980-06-17 Sterling Drug Inc. 11-Lower-alkyl-, 11-phenyl-lower-alkyl- and 11-cyclo-lower-alkyl-lower-alkyl-hexahydro-2,6-methano-3-benzazocines
DE4121821A1 (de) * 1991-07-02 1993-01-14 Boehringer Ingelheim Kg Neue benzomorphane und ihre verwendung als arzneimittel
US5607941A (en) * 1992-06-26 1997-03-04 Boehringer Ingelheim Kg Useful for treating neurodegenerative diseases
DE19528472A1 (de) * 1995-08-03 1997-02-06 Boehringer Ingelheim Kg Neues Verfahren zur Herstellung von Norbenzomorphan einer Zwischenstufe bei Herstellung von pharmazeutisch wertvollen Benzomorphanderivaten, insbesondere von (-)-(1R,5S,S"R)-3'-Hydroxy-2-(2-methoxypropyl-)-5,9,9-trimethyl-6,7 benzomorphan

Also Published As

Publication number Publication date
CZ296909B6 (cs) 2006-07-12
SA98190765B1 (ar) 2006-06-10
CO5011117A1 (es) 2001-02-28
BG104232A (en) 2000-10-31
KR100601008B1 (ko) 2006-07-19
DE59811477D1 (de) 2004-07-01
YU12000A (sh) 2002-11-15
DK1015433T3 (da) 2004-09-27
RU2218334C2 (ru) 2003-12-10
NZ503710A (en) 2002-04-26
PL198486B1 (pl) 2008-06-30
PL339061A1 (en) 2000-12-04
US6455538B1 (en) 2002-09-24
EP1015433A1 (de) 2000-07-05
HRP980502B1 (en) 2005-02-28
NO20001288D0 (no) 2000-03-10
HUP0004588A2 (hu) 2001-07-30
SK284670B6 (sk) 2005-08-04
EP1015433B1 (de) 2004-05-26
JP3827528B2 (ja) 2006-09-27
AU9624298A (en) 1999-04-05
BR9812443A (pt) 2000-09-26
ZA988285B (en) 1999-03-12
NO20001288L (no) 2000-03-13
BG64418B1 (bg) 2005-01-31
TR200000697T2 (tr) 2001-01-22
UY25175A1 (es) 2000-12-29
IL134572A0 (en) 2001-04-30
HUP0004588A3 (en) 2002-10-28
CA2302347C (en) 2008-06-17
JP2001516747A (ja) 2001-10-02
SK3342000A3 (en) 2000-09-12
RS49888B (sr) 2008-08-07
PE122899A1 (es) 1999-12-06
TW505645B (en) 2002-10-11
UA61973C2 (en) 2003-12-15
ES2222612T3 (es) 2005-02-01
NO315650B1 (no) 2003-10-06
ATE267811T1 (de) 2004-06-15
MY120550A (en) 2005-11-30
CN1166640C (zh) 2004-09-15
AU751036B2 (en) 2002-08-08
DE19740110A1 (de) 1999-03-18
UY25439A1 (es) 1999-11-17
PT1015433E (pt) 2004-08-31
ID24173A (id) 2000-07-13
WO1999014199A1 (de) 1999-03-25
CN1269790A (zh) 2000-10-11
HRP980502A2 (en) 1999-06-30
KR20010023879A (ko) 2001-03-26
EE04398B1 (et) 2004-12-15
EE200000129A (et) 2001-02-15
CZ2000894A3 (cs) 2000-09-13
CA2302347A1 (en) 1999-03-25
IL134572A (en) 2005-05-17

Similar Documents

Publication Publication Date Title
AR017095A1 (es) 1,2,3,4,5,6-hexahidro-2,6-metano-3-benzazocin-10-oles, procedimiento para su preparacion, metodo para la elaboracion de un compuesto intermedio del procedimiento, preparacion farmaceutica que los contiene y su empleo como o en medicamento
ES2611657T3 (es) Inhibidores de pirazol-carboxamida del factor Xa
AR035861A1 (es) Compuestos aminoacidos biciclicos o triciclicos condensados, procedimiento de preparacion, composiciones farmaceuticas y su uso en la preparacion de medicamentos
DE69822214D1 (de) ((cyclo)alkyl substituierte)-.gamma.-aminobuttersäure derivate (=gaba analoga), deren herstellung und deren verwendung bei der behandlung von neurologischen erkrankungen
TR200000671T2 (tr) FP agonistleri olarak yararlı aromatik C16-C20-ikameli tetrahidro prostaglandinler.
RU99115750A (ru) Новые соединения с анальгезирующим действием
TR200000673T2 (tr) FP agonistleri olarak yararlı aromatik C16-C20- ikameli tetrahidro prostaglandinler.
BR9713186A (pt) Inibidores de metaloprotease 1,3-diheterocìclicos
ES2081187T3 (es) Nuevas naftil-alquil-aminas, su procedimiento de preparacion y composiciones farmaceuticas que las contienen.
IS6459A (is) Arýl sambrædd azapólýsýklísk efnasambönd
TR200000670T2 (tr) FP agonistleri olarak yararlı aromatik C16-C20- ikameli tetrahidro prostaglandinler.
AR044013A1 (es) Derivados de acido [2-(8,9-dioxo-2,6-diazabiciclo [5.2.0.] non-1 (7)-en-2-il)alquil]fosfonico, metodos para su uso, composicion y procedimiento de preparacion
PT94297A (pt) Processo para a preparacao de n-hetero-aril-purin-6-aminas e de composicoes farmaceuticas que as contem
DK0451654T3 (da) Anvendelse af N-alkylerede 1,4-dihydropyridin-dicarboxylsyreestere som lægemidler, nye forbindelser og fremgangsmåder til deres fremstilling
YU224790A (sh) Aminokarbonil karbamati, sorodni fizostigminu/in postopek za njihovo pripravo in njihova uporaba kot zdravila
FI942976A (fi) 5-amino-8-metyyli-7-pyrrolidinyylikinoliini-3-karboksyylihappojohdannaiset
FR2393577A1 (fr) Medicament a base d'acide b-(p-halogenophenyl)-g-aminobutyrique destine au traitement de la nevrose d'angoisse
ES2307671T3 (es) Compuestos de gaba n-alquilados, procedimientos para su preparacion y su uso como medicamentos.
FR2395272A1 (fr) Nouveaux medicaments derives de l'acide amidinopenicillanique
FR2404010A1 (fr) Nouveaux derives de pyrimido-(2,1-a)isoquinoleine, leur procede de production et composition pharmaceutique les contenant
WO2019104041A1 (en) Dihydropyridines for the treatment of cognitive impairment or traumatic brain injury
AR009374A1 (es) Compuestos novedosos antagonistas de nmda (n-metil-d-aspartato), composicion farmaceutica y usos para fabricar medicamentos.
ES2077473T3 (es) Nuevos compuestos tiocromanicos, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
IT1279530B1 (it) Composizioni farmaceutiche a base di derivati del bicicloeptano, procedimento per la loro preparazione e loro impiego
DK121789A (da) 4,5,6,7-tetrahydroisothiazole oe4,5-caapyridinderivater

Legal Events

Date Code Title Description
FG Grant, registration